Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 03, 2023 12:03pm

205 Views

Post# 35265065

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

Yes we wait. And as we wait more evidence continues to appear as to why the acquisition of a bolt-on platform technology easily falls within Big Pharma's "sweet spot" of US $5 to15 Billion, while some, like AstraZeneca's bolt-on acquistion of Alexion was completed for US$39 Billion.

https://www.mccarthy.ca/en/work/cases/astrazeneca-agrees-acquire-alexion-pharmaceuticals-inc-us39b

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario